Clinical Trials Browser

Phase 1 × Completed × Ipilimumab × Clear all

NCT04465643 2026-05-29

Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

Phase 1 Completed

Nerve Sheath Neoplasms

NCT03600155 2026-05-15

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04290546 2026-02-27

CIML NK Cell in Head & Neck Cancer

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT04362839 2026-01-28

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03388632 2025-12-18

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Phase 1 Completed

31 enrolled 20 charts

Other solid neoplasm

Metastatic Solid Tumors

NCT03245892 2025-12-17

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Phase 1 Completed

High Grade Serous Ovarian

NCT04850755 2025-09-25

A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

Phase 1 Completed

Advance Solid Malignancies

NCT05004025 2025-08-15

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Phase 1 Completed

Uveal Melanoma

NCT05444530 2025-07-20

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Phase 1 Completed

Myeloproliferative Disorders

NCT03508570 2025-05-22

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Phase 1 Completed

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT01703507 2025-05-16

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

Phase 1 Completed

17 enrolled 15 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03922880 2025-05-15

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

Phase 1 Completed

Uveal Melanoma

NCT04463368 2025-03-28

SCANDIUM II

Phase 1 Completed

Uveal Melanoma

NCT02922764 2025-03-26

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Phase 1 Completed

GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT03387761 2025-03-05

NABUCCO

Phase 1 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT03956680 2025-02-19

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Phase 1 Completed

Advanced Solid Cancers

NCT04121676 2025-01-13

Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Phase 1 Completed

Melanoma

NCT04855929 2024-11-08

ANV419-001

Phase 1 Completed

Disease, Lung Neoplasms, Neoplasms, Recurrence

NCT05169957 2024-11-05

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Phase 1 Completed

Uveal Melanoma, Melanoma

NCT03523819 2024-09-19

A Study of CS1002 in Subjects with Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumor, Adult

NCT03752398 2024-07-05

DUET-3

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03829111 2024-07-03

CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer

Phase 1 Completed

Carcinoma, Renal Cell

NCT04518046 2024-06-05

Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Phase 1 Completed

Carcinoma, Renal Cell

NCT01621490 2024-04-23

PD-1

Phase 1 Completed

170 enrolled 34 charts

Melanoma

NCT03798639 2024-04-12

Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer

Phase 1 Completed

Carcinoma, Merkel Cell

NCT01738139 2024-03-21

Ipilimumab and Imatinib Mesylate in Advanced Cancer

Phase 1 Completed

DermatologicGastrointestinalSarcoma

Melanoma, Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT03373188 2024-03-20

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT03728179 2024-02-20

RACIN

Phase 1 Completed

Other solid neoplasm

Solid Tumor, Adult

NCT02467361 2023-11-14

A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

Phase 1 Completed

Neoplasms

NCT03425292 2023-11-08

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Phase 1 Completed

Newly Diagnosed High Grade Glioma

NCT04721301 2023-10-17

Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial

Phase 1 Completed

Gastrointestinal

Colorectal Cancer Metastatic

NCT01176474 2023-07-19

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Phase 1 Completed

Melanoma

NCT01935921 2023-06-15

Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT00790010 2023-05-11

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Phase 1 Completed

Melanoma

NCT03408587 2023-05-06

CLEVER

Phase 1 Completed

Diabetes Mellitus, Insulin-Dependent, 12, Uveal Melanoma, Coxsackievirus Infections, Virus Diseases

NCT03507699 2023-04-18

Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Colonic Neoplasms

NCT04084951 2023-04-14

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

Neoplasm Metastasis, Neoplasms, Recurrence

NCT03305445 2023-02-15

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

Phase 1 Completed

Lymphoma, Large B-Cell, Diffuse

NCT02032810 2023-01-20

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

Phase 1 Completed

17 enrolled 12 charts

Melanoma, Skin Neoplasms

NCT02829931 2023-01-19

Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

Phase 1 Completed

Glioma

NCT02307149 2023-01-17

MITCI

Phase 1 Completed

Melanoma

NCT02311920 2023-01-10

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 1 Completed

Gliosarcoma

NCT04132817 2022-12-02

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

Phase 1 Completed

Breast Neoplasms

NCT02659540 2022-10-28

Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma

Phase 1 Completed

20 enrolled 15 charts

Melanoma

NCT03335540 2022-09-26

ADVISE

Phase 1 Completed

Advanced Cancer

NCT03532217 2022-08-05

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Phase 1 Completed

Metastatic Hormone-Sensitive Prostate Cancer

NCT02977156 2022-07-25

ISI-JX

Phase 1 Completed

Neoplasm Metastasis

NCT03525795 2022-05-18

ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT03203876 2022-03-10

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

Phase 1 Completed

Advanced Cancer

NCT02381314 2022-02-08

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Phase 1 Completed

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma